Get the Stockscreener App
2.36
2.61%
0.06
After Hours:
2.42
0.06
+2.54%
Aytu Biopharma Inc stock is traded at $2.36, with a volume of 69,980.
It is up +2.61% in the last 24 hours and up +4.89% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
See More
Previous Close:
$2.30
Open:
$2.295
24h Volume:
69,980
Relative Volume:
0.47
Market Cap:
$21.19M
Revenue:
$93.76M
Net Income/Loss:
$-13.68M
P/E Ratio:
-0.8973
EPS:
-2.63
Net Cash Flow:
$8.77M
1W Performance:
+4.89%
1M Performance:
+4.89%
6M Performance:
+85.83%
1Y Performance:
-6.35%
1-Day Range:
$2.29
$2.40
1-Week Range:
$2.165
$2.40
52-Week Range:
$0.95
$2.85
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.36 | 20.47M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Price momentum metrics for Aytu BioPharma Inc. explained2025 Institutional Moves & Weekly Top Performers Watchlists - Newser
Quantitative breakdown of Aytu BioPharma Inc. recent moveTrade Volume Report & Weekly Market Pulse Updates - Newser
quantitative breakdown of aytu biopharma inc. recent moveTrade Performance Summary & Target Return Focused Stock Picks - Newser
What Fibonacci levels say about Aytu BioPharma Inc. reboundJuly 2025 Pullbacks & Risk Adjusted Buy/Sell Alerts - Newser
Applying Wyckoff theory to Aytu BioPharma Inc. stockTrend Reversal & Capital Protection Trade Alerts - Newser
Is Aytu BioPharma Inc. trending in predictive chart models2025 Price Targets & AI Optimized Trading Strategy Guides - Newser
Is Aytu BioPharma Inc. forming a bottoming baseJuly 2025 Gainers & Low Drawdown Investment Strategies - Newser
Using Ichimoku Cloud for Aytu BioPharma Inc. technicalsJuly 2025 Weekly Recap & High Conviction Buy Zone Alerts - Newser
Key metrics from Aytu BioPharma Inc.’s quarterly dataSell Signal & Accurate Technical Buy Alerts - Newser
Will Aytu BioPharma Inc. stock recover after recent dropBull Run & Free Long-Term Investment Growth Plans - Newser
Multi factor analysis applied to Aytu BioPharma Inc.July 2025 Catalysts & Weekly High Momentum Picks - Newser
Aytu BioPharma Inc. (NASDAQ:AYTU) Short Interest Update - Defense World
price momentum metrics for aytu biopharma inc. explainedJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - Newser
Analyzing Aytu BioPharma Inc. with risk reward ratio charts2025 Market Sentiment & Risk Managed Trade Strategies - Newser
How to use a screener to detect Aytu BioPharma Inc. breakoutsJuly 2025 Levels & Low Risk High Reward Trade Ideas - Newser
Can Aytu BioPharma Inc. recover in the next quarterMarket Activity Report & Target Return Focused Stock Picks - Newser
Risk vs reward if holding onto Aytu BioPharma Inc.July 2025 Momentum & Reliable Intraday Trade Alerts - Newser
Chart overlay techniques for tracking Aytu BioPharma Inc.Market Trend Report & Fast Entry Momentum Alerts - Newser
Is Aytu BioPharma Inc. stock entering bullish territoryLong Setup & Weekly Top Performers Watchlists - Newser
Risk adjusted return profile for Aytu BioPharma Inc. analyzedJuly 2025 Short Interest & Weekly Chart Analysis and Guides - Newser
Is Aytu BioPharma Inc. showing signs of accumulationAnalyst Upgrade & Accurate Intraday Trade Tips - Newser
Will Aytu BioPharma Inc. rebound enough to break evenJuly 2025 Update & Verified Momentum Stock Watchlist - Newser
Using Python tools to backtest Aytu BioPharma Inc. strategiesJuly 2025 Rallies & Safe Swing Trade Setup Alerts - Newser
will breakout in aytu biopharma inc. lead to full recoveryPortfolio Risk Summary & Fast Gaining Stock Strategy Reports - Newser
Identifying reversal signals in Aytu BioPharma Inc.Weekly Stock Recap & Accurate Entry/Exit Alerts - Newser
Custom watchlist performance reports with Aytu BioPharma Inc.Earnings Growth Summary & Real-Time Chart Breakout Alerts - Newser
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):